Subscribe To
PIRS / Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Why
PIRS News
By Zacks Investment Research
September 25, 2023
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Why
Pieris Pharmaceuticals (PIRS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. T more_horizontal
By Zacks Investment Research
August 23, 2023
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should Know
Pieris Pharmaceuticals (PIRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 more_horizontal
By Zacks Investment Research
July 19, 2023
Pieris (PIRS) Pursues Strategic Alternatives, Stock Rises
Pieris (PIRS) announces strategic update after partner AstraZeneca terminated collaboration agreement and returned the rights to elarekibep. more_horizontal
By Zacks Investment Research
June 23, 2023
Pieris (PIRS) Declines as AZN Halts Study of Asthma Candidate
Pieris' (PIRS) shares nosedive as its partner decides to discontinue a phase IIa study evaluating elarekibep for treating asthma, based on non-clinica more_horizontal
By Seeking Alpha
May 17, 2023
Pieris Pharmaceuticals: Expanding Elarekibep (AZD1402) Trial Finally Has Active And Completed Sites
Expanding Elarekibep (AZD1402) trial finally has active/completed sites. Major investment risk exists because of the Company's cash burn rate. more_horizontal
By PennyStocks
May 12, 2023
Best Penny Stocks To Buy Now? 7 Under $1 To Watch
Penny stocks under $1 to watch before next week. The post Best Penny Stocks To Buy Now? more_horizontal
By Zacks Investment Research
May 10, 2023
Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates
Pieris Pharmaceuticals (PIRS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares more_horizontal
By Seeking Alpha
March 29, 2023
Pieris Pharmaceuticals, Inc. (PIRS) Q4 2022 Earnings Call Transcript
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ) Q4 2022 Results Earnings Conference Call March 29, 2023 8:00 AM ET Company Participants Thomas Bures - Sen more_horizontal